 4D pharma PLC LON:DDD NASDAQ:LBPS said it has provided a more detailed analysis of its Live Biotherapeutic, Blautix, which is both significant and supportive of its continued development as an irritable bowel syndrome treatment. The data, presented as a poster at the medical and scientific conference Digestive Disease Week, builds on the top-line results released last October. 